Home / u-Plasminogen Activator (uPA)/Urokinase / Human u-Plasminogen Activator (uPA)/
Urokinase Catalytic Domain Antibody

Human u-Plasminogen Activator (uPA)/
Urokinase Catalytic Domain Antibody

Catalog #: MAB1310
5 Citations Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
MAB1310-SP
MAB1310-500
MAB1310-100
Product Details
Citations (5)
FAQs
Supplemental Products
Reviews
Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human u-Plasminogen Activator (uPA)/
Urokinase Catalytic Domain Antibody Summary

Species Reactivity
Human
Specificity
Detects human u-Plasminogen Activator (uPA)/Urokinase Catalytic Domain in direct ELISAs and Western blots. In Western blots under reducing conditions, it reacts with the catalytic domain (B chain) only. In Western blots under non-reducing conditions, it reacts with the B chain and disulfide bond-linked B and A chains. In direct ELISAs, no cross-reactivity with recombinant human (rh) Factor X, rhHGFA, rhKLK‑3, -4, -5, -6, -8, -10, -11, rhThrombin, or recombinant mouse WIF-1 is observed.
Source
Monoclonal Mouse IgG2A Clone # 204212
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human u-Plasminogen Activator (uPA)/Urokinase Catalytic Domain
Ser21-Leu431
Accession # P00749
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
Recombinant Human u-Plasminogen Activator (uPA)/Urokinase (Catalog # 1310-SE)
Immunoprecipitation
25 µg/mL
Conditioned cell culture medium spiked with Recombinant Human u-Plasminogen Activator (uPA)/Urokinase (Catalog # 1310-SE), see our available Western blot detection antibodies

Human u-Plasminogen Activator/Urokinase Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human u-Plasminogen Activator (uPA)/Urokinase Biotinylated Antibody (Catalog # BAF1310)

Standard: Recombinant Human u-Plasminogen Activator/Urokinase, CF (Catalog # 1310-SE)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: u-Plasminogen Activator (uPA)/Urokinase

uPA is a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin (1). uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium (2). For example, the combination (both low vs. either or both high) of uPA and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), outperforms the single factors as well as other traditional prognostic factors with regard to risk group assessment for breast cancer, particularly in node-negative breast cancer (3). The human uPA is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide (20 residues) (4‑6). The single chain molecule is processed into a disulfide-linked two-chain molecule. The B chain starting at Ile179 corresponds to the catalytic domain. Two forms of the A chain exist, one starting at Ser21 (the long form) and the other at Lys156 (the short form). The resulting two-chain forms have different molecular weights (MW). The B chain is common for both forms whereas the long and short A chains are unique to the high and low MW forms, respectively. The long A chain contains an EGF-like domain, which is responsible for binding of the uPA receptor (uPAR).

References
  1. Ellis, V. (2004) in Handbook of Proteolytic Enzymes. Barrett, A.J. et al. eds., Academic Press, San Diego, pp.1677.
  2. Duffy, M.J. (2002) Biochem. Soc. Trans. 30:207.
  3. Harbeck, N. et al. (2002) Clin. Breast Cancer 3:196.
  4. Riccio, A. et al. (1985) Nucleic Acids Res. 13:2785.
  5. Nagai, M. et al. (1985) Gene 36:183.
  6. Jacobs, P. et al. (1985) DNA 4:139.
Long Name
Urokinase-type Plasminogen Activator
Entrez Gene IDs
5328 (Human); 18792 (Mouse); 102135886 (Cynomolgus Monkey)
Alternate Names
ATF; EC 3.4.21; EC 3.4.21.73; plasminogen activator, urokinase; PLAU; uPA; u-PA; uPlasminogen Activator; u-Plasminogen Activator; urinary; Urokinase; urokinase-type plasminogen activator

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human u-Plasminogen Activator (uPA)/
Urokinase Catalytic Domain Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Filter by:

  1. Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA
    Authors: Huajiao Guo, Fuhao Wang, Yuwen Diao, Zhe Zhang, Qiuyan Chen, Chao‐Nan Qian et al.
    Molecular Carcinogenesis
  2. Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-beta/SMAD signaling.
    Authors: Devine D, Rostas J, Metge B, Das S, Mulekar M, Tucker J, Grizzle W, Buchsbaum D, Shevde L, Samant R
    Oncogene, 2013-06-17;33(20):2620-8.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  3. Transcription Factor AP-2alpha Promotes EGF-Dependent Invasion of Human Trophoblast.
    Authors: Biadasiewicz K, Sonderegger S, Haslinger P, Haider S, Saleh L, Fiala C, Pollheimer J, Knofler M
    Endocrinology, 2011-02-08;152(4):1458-69.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  4. AP-1-controlled hepatocyte growth factor activation promotes keratinocyte migration via CEACAM1 and urokinase plasminogen activator/urokinase plasminogen receptor.
    Authors: Schnickmann S, Camacho-Trullio D, Bissinger M, Eils R, Angel P, Schirmacher P, Szabowski A, Breuhahn K
    J. Invest. Dermatol., 2008-11-20;129(5):1140-8.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  5. GLIPR1 Protects Against Cigarette Smoke-Induced Airway Inflammation via PLAU/EGFR Signaling
    Authors: Wenjun Peng, Yuanyuan Wu, Ge Zhang, Wensi Zhu, Meijia Chang, Ainiwaer Rouzi et al.
    International Journal of Chronic Obstructive Pulmonary Disease

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human u-Plasminogen Activator (uPA)/
Urokinase Catalytic Domain Antibody

There are currently no reviews for this product. Be the first to review Human u-Plasminogen Activator (uPA)/
Urokinase Catalytic Domain Antibody and earn rewards!

Have you used Human u-Plasminogen Activator (uPA)/
Urokinase Catalytic Domain Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review